Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Senescence modulated cardiac repair with pluripotent stem cell-derived cardiomyocytes.

Stem cell research & therapy·2026
Same author

System Architecture of a Local Hybrid AI for Secure Patient Communication: Implementation on Consumer Hardware.

Studies in health technology and informatics·2026
Same author

miR-136-5p Preferentially Suppresses Cancer Stem-like Cells in Pancreatic Cancer.

International journal of molecular sciences·2026
Same author

First Japanese Experience of Robotic-Assisted Low Anterior Resection Using the da Vinci 5: Incorporating Force Feedback and Case Insights in Rectal Cancer Surgery.

Surgical case reports·2026
Same author

Correction to: CT colonography for assessing visceral obesity: clinical utility beyond colorectal screening.

Abdominal radiology (New York)·2026
Same author

Combination of color-related genes regulates pigment composition and establishes diverse coloration in soybean.

Plant physiology and biochemistry : PPB·2026
Same journal

Characterization of distant metastases in salivary gland cancer patients undergoing upfront surgery followed by postoperative radiation therapy: a multicenter analysis.

Japanese journal of clinical oncology·2026
Same journal

A Lynch syndrome patient with multiple cancers who was found to have a novel pathogenic variant generating aberrant splicing of MLH1.

Japanese journal of clinical oncology·2026
Same journal

Age-standardized mortality-to-incidence ratio for lymphoma in the world.

Japanese journal of clinical oncology·2026
Same journal

Real-world trends in anti-androgen prescribing and associated costs for prostate cancer in Japan: a nationwide analysis.

Japanese journal of clinical oncology·2026
Same journal

Progress in siRNA nucleic acid therapeutics and challenges in their application to cancer treatment.

Japanese journal of clinical oncology·2026
Same journal

Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.

Japanese journal of clinical oncology·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4
13:02

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4

Published on: April 7, 2008

Emerging methods for preparing iPS cells.

Susumu Miyazaki1, Hirofumi Yamamoto, Norikatsu Miyoshi

  • 1Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan.

Japanese Journal of Clinical Oncology
|July 25, 2012
PubMed
Summary
This summary is machine-generated.

Reprogramming somatic cells using microRNAs offers a safer alternative to viral methods for generating induced pluripotent stem cells. This approach reduces mutation and tumorigenesis risks, paving the way for safer regenerative medicine and cancer therapies.

More Related Videos

Cell Surface Marker Mediated Purification of iPS Cell Intermediates from a Reprogrammable Mouse Model
10:32

Cell Surface Marker Mediated Purification of iPS Cell Intermediates from a Reprogrammable Mouse Model

Published on: September 6, 2014

Deriving Retinal Pigment Epithelium (RPE) from Induced Pluripotent Stem (iPS) Cells by Different Sizes of Embryoid Bodies
09:18

Deriving Retinal Pigment Epithelium (RPE) from Induced Pluripotent Stem (iPS) Cells by Different Sizes of Embryoid Bodies

Published on: February 4, 2015

Related Experiment Videos

Last Updated: May 20, 2026

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4
13:02

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4

Published on: April 7, 2008

Cell Surface Marker Mediated Purification of iPS Cell Intermediates from a Reprogrammable Mouse Model
10:32

Cell Surface Marker Mediated Purification of iPS Cell Intermediates from a Reprogrammable Mouse Model

Published on: September 6, 2014

Deriving Retinal Pigment Epithelium (RPE) from Induced Pluripotent Stem (iPS) Cells by Different Sizes of Embryoid Bodies
09:18

Deriving Retinal Pigment Epithelium (RPE) from Induced Pluripotent Stem (iPS) Cells by Different Sizes of Embryoid Bodies

Published on: February 4, 2015

Area of Science:

  • Stem cell biology
  • Molecular biology
  • Regenerative medicine

Background:

  • Human embryonic stem cells (hESCs) show promise for regenerative medicine but face challenges like transplant rejection and bioethical concerns.
  • Induced pluripotent stem cells (iPSCs) overcome some hESC limitations but carry risks of tumorigenesis due to oncogene integration (c-Myc) and viral vectors.
  • Current gene transduction methods for reprogramming carry risks of genomic integration and tumor formation, limiting clinical applications.

Purpose of the Study:

  • To develop a safer method for generating induced pluripotent stem cells (iPSCs) by avoiding viral vectors and genomic integration.
  • To investigate the potential of microRNAs (miRNAs) for direct reprogramming of somatic cells into a pluripotent state.
  • To explore the therapeutic potential of miRNA-mediated reprogramming for regenerative medicine and cancer treatment.

Main Methods:

  • Somatic cells were reprogrammed by transfecting them with specific mature microRNAs (mir-200c, -302s, and -369s).
  • The expression levels of these miRNAs were confirmed to be increased in embryonic stem cells and induced pluripotent stem cells.
  • Transcription factors (Oct3/4, Sox2, c-Myc, Klf4) were introduced into cancer cells to generate induced pluripotent cancer cells.

Main Results:

  • MicroRNA-mediated reprogramming successfully converted mouse and human somatic cells into a pluripotent state.
  • MicroRNA-induced pluripotent stem cells exhibited reduced risks of mutations and tumorigenesis compared to traditional iPSCs.
  • Induced pluripotent cancer cells displayed significantly reduced malignant features, suggesting potential therapeutic applications.

Conclusions:

  • MicroRNA-based reprogramming offers a safer, non-viral alternative for generating pluripotent stem cells, minimizing risks associated with genomic integration.
  • This approach holds promise for advancing regenerative medicine and developing novel cancer therapies with reduced tumorigenic potential.
  • Further research is needed to optimize miRNA-based reprogramming for safe and efficient clinical applications, particularly in cancer treatment.